Response to aflibercept after frequent re-treatment with bevacizumab or ranibizumab in eyes with neovascular AMD

Ophthalmic Surgery Lasers and Imaging Retina

Volumn 45, Issue 6, 2014, Pages 526-533

  Thorell, Mariana R ^a   Nunes, Renata Portella ^b   Chen, Gene W ^a   Doshi, Rishi R ^a   Dugar, Jyoti ^a   George, Mathew K ^a   Kim, Brian T ^a   Lowrance, Matthew D ^a   Modi, Dimple ^a   Nahas, Zayna ^a   Gregori, Giovanni ^a   Yehoshua, Zohar ^a   Feuer, William ^a   Rosenfeld, Philip J ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; B SCAN; CENTRAL RETINAL THICKNESS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; OPTICAL COHERENCE TOMOGRAPHY DEVICE; OUTCOME ASSESSMENT; PIGMENT EPITHELIUM; RETINA DETACHMENT; RETREATMENT; RETROSPECTIVE STUDY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL ACUITY; WET MACULAR DEGENERATION; ANTAGONISTS AND INHIBITORS; INTRAVITREAL DRUG ADMINISTRATION; OPTICAL COHERENCE TOMOGRAPHY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG SUBSTITUTION; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETREATMENT; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84918520233     PISSN: 23258160     EISSN: 23258179     Source Type: Journal    
DOI: 10.3928/23258160-20141118-07     Document Type: Article

References (30)

1. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
2. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verte-porfn photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology. 2009;116(1):57-65 e5.
3. Schmidt-Erfurth U, Kaiser PK, Korobelnik J F, et al. Intravitreal afibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology. 2014;121(1):193-201.
4. Comparison of Age-related Macular Degeneration Treatments Trials Research Group, Martin D F, Maguire MG, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119(7):1388-1398.
5. Chakravarthy U, Harding S P, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year fndings of the IVAN randomised controlled trial. Lancet. 2013;382(9900):1258-1267.
6. Krebs I, Schmetterer L, Boltz A, et al. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol. 2013;97(3):266-271.
7. Kodjikian L, Souied EH, Mimoun G, et al. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology. 2013;120(11):2300-2309.
8. Busbee BG, Ho AC, Brown DM, et al. Twelve-month effcacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfove-al neovascular age-related macular degeneration. Ophthalmology. 2013;120(5):1046-1056.
9. Stewart MW, Rosenfeld PJ, Penha FM, et al. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibi-zumab, bevacizumab, and afibercept (vascular endothelial growth factor Trap-eye). Retina. 2012;32(3):434-457.
10. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related li-gands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171-185.
11. Stewart MW. Pharmacokinetics, pharmacodynamics and pre-clinical characteristics of ophthalmic drugs that bind VEGF. Expert Rev Clin Pharmacol. 2014;7(2):167-180.
12. Jeng K W, Wilgucki J, Halperin S, et al. Retina specialists treating age-related macular degeneration recommend different approaches for patients than they would choose for themselves. Retina. 2014;34(9):1796-1801.
13. Abedi F, Wickremasinghe S, Islam AF, et al. Anti-VEGF treatment in neovascular age-related macular degeneration: a treat-and-extend protocol over 2 years. Retina. 2014;34(8):1531-1538.
14. Xing L, Dorrepaal SJ, Gale J. Survey of intravitreal injection techniques and treatment protocols among retina specialists in Canada. Can J Ophthalmol. 2014;49(3):261-266.
15. Rosenfeld PJ, Moshfeghi AA, Puliafto CA. Optical coherence tomography fndings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging. 2005;36(4):331-335.
16. Penha FM, Rosenfeld PJ, Gregori G, et al. Quantitative imaging of retinal pigment epithelial detachments using spectral-domain optical coherence tomography. Am J Ophthalmol. 2012;153(3):515-523.
17. Gregori G, Wang F, Rosenfeld PJ, et al. Spectral domain optical coherence tomography imaging of drusen in nonexudative age-related macular degeneration. Ophthalmology. 2011;118(7):1373-1379.
18. Gregori NZ, Feuer W, Rosenfeld PJ. Novel method for analyzing snel-len visual acuity measurements. Retina. 2010;30(7):1046-1050.
19. Ho VY, Yeh S, Olsen TW, et al. Short-term outcomes of afibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Ophthalmol. 2013;156(1):23-28 e2.
20. Kumar N, Marsiglia M, Mrejen S, et al. Visual and anatomical outcomes of intravitreal afibercept in eyes with persistent subfoveal fuid despite previous treatments with ranibizumab in patients with neovas-cular age-related macular degeneration. Retina. 2013;33(8):1605-1612.
21. Cho H, Shah C P, Weber M, Heier JS. Afibercept for exudative AMD with persistent fuid on ranibizumab and/or bevacizumab. Br J Oph-thalmol. 2013;97(8):1032-1035.
22. Bakall B, Folk JC, Boldt HC, et al. Afibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibi-zumab. Am J Ophthalmol. 2013;156(1):15-22 e1.
23. Yonekawa Y, Andreoli C, Miller JB, et al. Conversion to afibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol. 2013;156(1):29-35 e2.
24. Heussen FM, Shao Q, Ouyang Y, et al. Clinical outcomes after switching treatment from intravitreal ranibizumab to afibercept in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2014;252(6):909-915.
25. Chang AA, Li H, Broadhead GK, et al. Intravitreal afibercept for treatment-resistant neovascular age-related macular degeneration. Ophthalmology. 2014;121(1):188-92.
26. Yonekawa Y. Afibercept for the treatment of refractory polypoidal choroidal vasculopathy. Can J Ophthalmol. 2013;48(3):e59-60.
27. Miura M, Iwasaki T, Goto H. Intravitreal afibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis. Clin Ophthalmol. 2013;7:1591-5.
28. Yamashita M, Nishi T, Hasegawa T, Ogata N. Response of serous retinal pigment epithelial detachments to intravitreal afibercept in polypoidal choroidal vasculopathy refractory to ranibizumab. Clin Ophthalmol. 2014;8:343-346.
29. Gambon R, Barthelmes D, Amstutz C, et al. Preliminary results of afibercept in treatment-naive choroidal neovascularization of wet age-related macular degeneration. Klin Monbl Augenheilkd. 2014;231(4):423-426.
30. Cheung CM, Mohla A, Wong TY. Resolution of persistent pigment epithelial detachment secondary to polypoidal choroidal vasculopathy in response to Afibercept. Eye (Lond). 2014;28(9):1148-1149.